AmacaThera is a Toronto-based biotechnology company developing innovative hydrogel drug delivery technologies that enable precise, localized, and sustained release of therapeutics. Founded in 2016 as a spin-out from the research laboratory of Molly Shoichet, the company is advancing a clinically validated platform designed to improve the delivery and effectiveness of a wide range of medicines.

Bringing together expertise in science, engineering, and business, AmacaThera partners with pharmaceutical companies to enhance existing and emerging therapies across multiple therapeutic areas. Through its scalable hydrogel platform and collaborative approach, the company is working to accelerate drug development and improve patient outcomes worldwide.